CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be
a) a guide for reporting for authors of RCTs,
b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.
Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.
In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).
Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: http://www.jmir.org/2011/4/e126/
doi: 10.2196/jmir.1923

https://docs.google.com/forms/d/e/1FAIpQLSIZBSUp1bwOc_Oimqe564RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q1l
PMID: 22209829

laurahesseldal@gmail.com (deles ikke) Skift konto

Kladden blev gemt

*Skal udfyldes

Your name *
First Last

Laura Hesseldal

Primary Affiliation (short), City, Country *
University of Toronto, Toronto, Canada

Research Unit for General Practice, Department

Your e-mail address *

abc@gmail.com

lhesseldal@health.sdu.dk

Title of your manuscript *
Provide the (draft) title of your manuscript.

Long term Weight Loss in a Primary Care-Anchored eHealth Lifestyle Coaching Program in Denmark: Randomized Controlled Trial
Name of your App/Software/Intervention *
If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

LIVA, an eHealth tool

Evaluated Version (if any)
e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Version 2.0

Language(s) *
What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Danish, English, German, Flemish, Swedish, Fir

URL of your Intervention Website or App
e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://liva-start.com/fr-en/?lang=en-fr

URL of an image/screenshot (optional)

Dit svar
Accessibility *
Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Andet:

Primary Medical Indication/Disease/Condition *
e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Obesity and diabetes

Primary Outcomes measured in trial *
comma-separated list of primary outcomes reported in the trial

Body Weight

Secondary/other outcomes
Are there any other outcomes the intervention is expected to affect?

Our secondary outcomes were changes in HbA1c. Tertiary outcomes were body composition (BMI and waist/hip ratio), lipids (total cholesterol, LDL-C, HDL-C, and TG) and blood pressure (systolic and diastolic), changes in Mental health, and Quality of life
Recommended "Dose" *
What do the instructions for users say on how often the app should be used?

- [ ] Approximately Daily
- [ ] Approximately Weekly
- [ ] Approximately Monthly
- [ ] Approximately Yearly
- [ ] "as needed"
- [ ] Andet:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months

- [ ] unknown / not evaluated
- [ ] 0-10%
- [ ] 11-20%
- [ ] 21-30%
- [ ] 31-40%
- [ ] 41-50%
- [ ] 51-60%
- [ ] 61-70%
- [ ] 71%-80%
- [ ] 81-90%
- [ ] 91-100%
- [ ] Andet:
Overall, was the app/intervention effective? *

- yes: all primary outcomes were significantly better in intervention group vs control
- partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed

Andet:

Article Preparation Status/Stage *
At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet - in early draft status
- not submitted yet - in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- published

Andet:
Journal *
If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Andet:

Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- Pilot/feasibility
- Fully powered

Manuscript tracking number *
If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

- no ms number (yet) / not (yet) submitted to / published in JMIR
- Andet:

TITLE AND ABSTRACT
1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under 'other')

- yes
- Andet:

1a-i) Identify the mode of delivery in the title
Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

- subitem not at all important
- essential

Ryd markering

Does your paper address subitem 1a-i? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Delivered by a "Primary Care-Anchored eHealth Lifestyle Coaching Program" as mentioned in the manuscript title.
1a-ii) Non-web-based components or important co-interventions in title
Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

1 2 3 4 5
subitem not at all important ◯ ◯ ◯ ◯ ◯ essential

Does your paper address subitem 1a-ii?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This paper does not include a co-intervention.

1a-iii) Primary condition or target group in the title
Mention primary condition or target group in the title, if any (e.g., “for children with Type I Diabetes”) Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1 2 3 4 5
subitem not at all important ◯ ◯ ◯ ◯ ◯ essential

Does your paper address subitem 1a-iii? *
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Out intervention (eHealth) is Primary Care Anchored. We included obese participants in age 18-70 year both with and without type 2 diabetes.
### 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

### 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| Subitem | Rating |
|---------|--------|
| 1       | not at all important |
| 2       |       |
| 3       |       |
| 4       | essential |
| 5       |       |

**Does your paper address subitem 1b-i?** *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes it is mentioned like this in the abstract: "The digital coaching intervention comprised of an initial one-hour face-to-face motivational interview followed by digital coaching using behavioral change techniques enabled by individual live monitoring." The intervention is described in more details in the manuscript.

### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like “fully automated” vs. “therapist/nurse/care provider/physician-assisted” (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| Subitem | Rating |
|---------|--------|
| 1       | not at all important |
| 2       |       |
| 3       |       |
| 4       | essential |
| 5       |       |

---

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIFvincrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q
Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Our intervention involved a health care professional (human) which is mentioned in the abstract "an initial one-hour face-to-face motivational interview". Afterward the intervention was asynchronous digital coaching "followed by digital coaching using behavioral change techniques enabled by individual live monitoring".

---

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it).

1 2 3 4 5

subitem not at all important ☐ ☐ ☐ ☐ ☑ essential

Ryd markering

---

Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes it is mentioned in the abstract like this: "Patients were recruited via their general practitioners, the Danish diabetes organization, and social media".
1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important  O  O  O  O  O essential

Ryd markering

Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks 'like this’ to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes first in the methods like this "In a randomized controlled trial that took place in 50 municipalities in Denmark, 340 subjects with obesity with or without T2D were enrolled from April 16, 2018 to April 1, 2019, and randomized via an automated computer algorithm to an intervention (200) or a control (140)" and afterwards in the results section more specified for this paper "Data were assessed for 235 participants, 149 from the intervention group and 86 from the control group who completed 6 and/or 12 months follow-up”

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important  O  O  O  O  O essential

Ryd markering
INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in “Methods” under 5)

Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Describing the problem "Unfortunately, it is difficult for people with obesity and T2D to achieve and maintain a long-term weight loss" which is why this study focused on a population of obese participants with and without Type 2 diabetes (T2D), and another problem mentioned in this paper "Even though general practice is supposed to support self-management and healthy lifestyle, studies have shown that the annual consultations seldom address lifestyle issues"
**2a-ii) Scientific background, rationale: What is known about the (type of) system**

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5

subitem not at all important

essential

Ryd markering

**Does your paper address subitem 2a-ii?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Metanalyses and systematic reviews show that electronic health (eHealth) and mobile health (mHealth) solutions are significantly better than usual care defined as routine diabetes self-care with no personalized feedback at supporting weight loss short term over 3-6 months for motivated patients with obesity [8,9]. An essential component of effective solutions is behavioral change techniques (BCT) involving automated, semi-automated, and/or human digital feedback [9,10]. Human feedback, particularly from healthcare professionals (HCPs), is most effective [11]." But as mentioned in the last part of our introduction "However, limited evidence exists about the potential for such solutions to lead to weight loss long term over 6 months."

**2b) In INTRODUCTION: Specific objectives or hypotheses**

**Does your paper address CONSORT subitem 2b?**

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes: "In this randomized controlled trial (RCT), we aimed to investigate whether digital coaching through a multifaceted eHealth tool can help subjects with obesity with and without T2D to achieve and sustain a more significant long term weight loss compared to an equally motivated control group receiving usual care."
METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes "This study was part of an RCT that took place in two of the five regions in Denmark; the Capital Region of Denmark with 28 municipalities and the Region of Southern Denmark with 22 municipalities" and "Participants were randomized to the intervention group who received usual care and digital lifestyle coaching or the control group who only received usual care preferred by patient and doctor. Randomization occurred after participants had completed the medical examination via an automated computer algorithm in groups of 10 at a ratio 6:4 where 60% of the recruited participants were randomized to the intervention group and the remaining 40% were included in the control group based on a pilot RCT"

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, due to COVID-19 restrictions: "Due to the COVID-19 lockdown and national restrictions, some participants could not attend their 12-months assessment. Therefore, the 12-months assessment period was extended with four months, covering 12-16 months follow-up after baseline"
3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/douttimes, etc. [2].

1 2 3 4 5
subitem not at all important ◯ ◯ ◯ ◯ ◯ essential

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes both our few inclusion criteria and exclusion criteria "After registration participants were contacted by phone by a research assistant, who made sure the participants met the inclusion criteria on BMI (BMI 30-45 kg/m2) and age (aged 18-70 years). Exclusion criteria were: 1) lack of internet access through computer or smartphone, 2) pregnancy or planned pregnancy, and 3) serious or life-threatening disease defined as less than one-year lifetime expectancy."
4a-i) Computer / Internet literacy
Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential                   |   |   |   |   |   |

Ryd markering

Does your paper address subitem 4a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes as an exclusion criteria "Exclusion criteria were: 1) lack of internet access through computer or smartphone"

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:
Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential                   |   |   |   |   |   |

Ryd markering
Does your paper address subitem 4a-ii?  *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes, participants were recruited online and offline "recruited through their local health care centers and general practitioners (GPs), the Danish diabetes organization and social media" Blinding was not possible "Blinding the participants, the research assistant, and the health coach who provided lifestyle coaching for all participants receiving the intervention was not possible after randomization. The research assistant and health coach had no role in analyzing or interpreting data."

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

1  2  3  4  5

subitem not at all important ☐ ☐ ☐ ☐ ☑ essential

Ryd markering

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes "After registration participants were contacted by phone by a research assistant, who made sure the participants met the inclusion criteria" and regarding consent "At the baseline meeting, participants gave written informed consent and informed the research assistant about their use of medication."

4b) Settings and locations where the data were collected
Does your paper address CONSORT subitem 4b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Only that it was assessed at baseline, 6 months and 12 months "At the baseline meeting, participants gave written informed consent and informed the research assistant about their use of medication. Afterwards, a brief medical examination was performed."

4b-i) Report if outcomes were (self-)assessed through online questionnaires
Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

1 2 3 4 5
subitem not at all important  ○ ○ ○ ○  ● essential

Does your paper address subitem 4b-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Outcomes in mental health score and Quality of Life was assessed by a online questionnaire "All participants filled out an online questionnaire on sociodemographic characteristics, the European Quality of life - 5 Dimensions scheme (EQ-5D-5L) and the Short-Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) [19,20]"

4b-ii) Report how institutional affiliations are displayed
Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)

1 2 3 4 5
subitem not at all important  ○ ○ ○ ○ ○  ● essential
Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a “Conflict of interest” section or mentioned elsewhere in the manuscript).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Ryd markering

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

It's mentioned in conflict of interest: "CJB has originally co-founded LIVA Healthcare A/S and owns stock in LIVA Healthcare A/S"
5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Subitem | not at all important | | | | essential |

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Briefly "As described in detail in the study protocol [12] this study’s collaborative eHealth tool called LIVA has been developed based on experiences from approximately 140,000 individuals, who used the collaborative eHealth tool version 1.0, over a period of 15 years [12]. Version 1.0 has been further developed into version 2.0 based on feedback from patients, general practitioners, and HCPs[13-15]" and more detailed in the protocol.

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Subitem | not at all important | | | | essential |

Ryd markering
Does your paper address subitem 5-iii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

The update form version 0.1 to version 0.2 is mentioned.

5-iv) Quality assurance methods
Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential                      |   |   |   |   |   |

Does your paper address subitem 5-iv?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Dit svar

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used
Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

|   | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| subitem not at all important |   |   |   |   |   |
| essential                      |   |   |   |   |   |
Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 5-vi?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

5-vii) Access
Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained “access to the platform and Internet” [1]. To ensure access for editors/reviewers/readers, consider to provide a “backdoor” login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Ryd markering
Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

It is only briefly described with a reference to the paper's study protocol: "Participants who would like to participate could then register at the eHealth tool URL."

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1], whether and how it is tailored to individual circumstances and allows users to track their progress and receive feedback [6]. This also includes a description of communication delivery channels and whether computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential
Ryd markering

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

It is described in Multimedia appendix 1 and mentioned in the method section like this: "After an initial 45-60 minutes consultation with the HCP the intervention group received the individualized digital lifestyle coaching using an eHealth tool to complete daily records and to send remarks directly to the HCP. Based on the individual goal setting created using the SMART (specific, measurable, attainable, relevant, timely) model [21] the health coach provided weekly asynchronous digital coaching for each participant inspiriting, commending goal attainment and seeking to help them stay motivated [13]. The subsequent asynchronous eHealth coaching sessions was carried out once a week in the first 6 months and then every month for the last 6 months for maintenance. The eHealth tool program is further described in the Template of the Intervention Description and Replication (TIDieR) (Supplementary Multimedia appendix 1). "

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqecS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGIlKd2ZQ… 24/52
5-ix) Describe use parameters

Describe use parameters (e.g., intended “doses” and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

1 2 3 4 5

subitem not at all important ○ ○ ○ ● ○ essential

Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"Based on the individual goal setting created using the SMART (specific, measurable, attainable, relevant, timely) model [21] the health coach provided weekly asynchronous digital coaching for each participant inspiring, commending goal attainment and seeking to help them stay motivated [13]. The subsequent asynchronous eHealth coaching sessions was carried out once a week in the first 6 months and then every month for the last 6 months for maintenance”

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as “type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered”. It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ● essential
Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Initially face-to-face and afterwards asynchronous digital coaching: "After an initial 45-60 minutes consultation with the HCP the intervention group received the individualized digital lifestyle coaching using an eHealth tool to complete daily records and to send remarks directly to the HCP. Based on the individual goal setting created using the SMART (specific, measurable, attainable, relevant, timely) model [21] the health coach provided weekly asynchronous digital coaching for each participant”

|      | 1   | 2   | 3   | 4   | 5   |
|------|-----|-----|-----|-----|-----|
| subitem not at all important | ○   | ○   | ○   | ●   | ○   |

Ryd markering

Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

"The health coach provided weekly asynchronous digital coaching for each participant inspiring, commending goal attainment and seeking to help them stay motivated“
5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as eHealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

1. subitem not at all important
2. 
3. 
4. essential
5. 

Ryd markering

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our paper does not have any co-intervention.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The primary outcome was reduction in mean body weight (BW) assessed as the difference between BW at baseline to 6 months and baseline to 12 months and as the difference divided by baseline BW. The proportion of participants who had a significant weight loss of > 5% of baseline BW [22] were also assessed at 6 and 12 months. Our secondary outcomes were changes in HbA1c from baseline to 6 and 12 months, respectively. Tertiary outcomes were body composition (BMI and waist/hip ratio), lipids (total cholesterol, LDL-C, HDL-C, and TG) and blood pressure (systolic and diastolic), changes in Mental health and Quality of life. All differences in tertiary outcomes were calculated from baseline to 6 months and baseline to 12 months."
6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5

subitem not at all important   essential

Does your paper address subitem 6a-i?
Copy and paste relevant sections from manuscript text

"All participants filled out an online questionnaire on sociodemographic characteristics, the European Quality of Life - 5 Dimensions scheme (EQ-5D-5L) and the Short-Warwick-Edinburgh Mental Well-being Scale (SWEMWBS) [19,20]. The EQ-5D-5L descriptive system comprises five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Responses are coded as single-digit numbers expressing the severity level selected in each dimension which are then coded into a score ranging from 0.35 to 1.0. The SWEMWBS is a 7-item scale covering subjective well-being and psychological functioning. Each item is answered on a five-point Likert scale going from: none of the time, rarely, some of the time, often, all the time. The summary index ranges from 7-35. Higher scores indicate higher well-being and psychological functioning [19,20]. The participants answered both questionnaires at baseline, 6- and 12-months follow up."

6a-ii) Describe whether and how “use” (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1 2 3 4 5

subitem not at all important   essential
Does your paper address subitem 6a-ii?
Copy and paste relevant sections from manuscript text

We looked into use of the app. As the participants had to do daily remarks a participants who fully used the app in 12 months = 365 days or more. "In addition, we have performed a per protocol analysis by using only data from participants who had been using the eHealth tool for 365 days or more"

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important |   |   |   | 3 |
|                              |   |   |   | essential |

Does your paper address subitem 6a-iii?
Copy and paste relevant sections from manuscript text

This paper does not include qualitative feedback from participants.

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There was no changes in the outcomes of the trial.
7a) How sample size was determined
NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size
Describe whether and how expected attrition was taken into account when calculating the sample size.

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Does your paper address subitem 7a-i?
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Through out this paper we explained and preformed analysis at both 6 months follow up and 12 months follow up.

8a) Method used to generate the random allocation sequence
NPT: When applicable, how care providers were allocated to each trial group
Does your paper address CONSORT subitem 8a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes."Randomization occurred after participants had completed the medical examination via an automated computer algorithm in groups."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes: "in groups of 10 at a ration 6:4 where 60% of the recruited participants were randomized to the intervention group and the remaining 40% were included in the control group based on a pilot RCT [16] as described in our protocol article [12]. Randomization was controlled to ensure that 50% of participants in the intervention group and control group would be obese citizens, who have not been previously diagnosed with T2D, and the other 50% of participants in the intervention group and control group would be pa diagnosed with T2D."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

This randomization was performed by a computer algorithm.
10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients were enrolled at baseline by a research assistant: "At the baseline meeting, participants gave written informed consent and informed the research assistant about their use of medication. Afterwards, a brief medical examination was performed" but "The research assistant and health coach who preformed the digital lifestyle coaching had no role in randomization, analyzing or interpreting data"

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn’t

Specify who was blinded, and who wasn’t. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ 五 essential

Ryd markering

Does your paper address subitem 11a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Blinding was not possible "Blinding the participants, the research assistant, and the health coach who provided lifestyle coaching for all participants receiving the intervention was not possible after randomization. The research assistant and health coach had no role in analyzing or interpreting data."
11a-ii) Discuss e.g., whether participants knew which intervention was the “intervention of interest” and which one was the “comparator”

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

It was clear to the participants if they were randomized to the intervention: "Participants were randomized to the intervention group who received usual care and digital lifestyle coaching or the control group who only received usual care preferred by patient and doctor."

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, because this is a eHealth trial.

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed
Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "The statistical significance of between-group differences in outcomes at 6 and 12 months was assessed with either one-way ANOVA or chi-squared test. Statistical significance was set at two-tailed P < 0.05"

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "To avoid missing values, we allowed imputation using values from 12-months follow-up in three participants failing to appear at 6-months follow-up and from 6-months follow-up in 32 participants failing to appear at 12-months follow-up. Supplementary we have repeated all the analyses without imputation."

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses
Does your paper address CONSORT subitem 12b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "Finally, we performed regression analysis including an interaction term to investigate whether participants with T2D responded differently to the intervention."

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |

Does your paper address subitem X26-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. "The study was approved by the scientific committee (S-20170183G) of the Region of Southern Denmark."

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |
RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center
Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. The results and number of participant in each group is included in table 2. Results are described in text. "235 participants came to follow-up after 6 or 12 months, 232 at 6 months and 200 at 12 months” and "BW was our primary outcome which was at 6 months significantly reduced by -4.0 (95% CI, -4.9; -3.2) kg in the intervention group and insignificant by -0.4 (95% CI, -1.2; 0.3) kg in the control group. The between-group difference was statistically significant (P<.005). After 12 months the BW was significantly reduced in both the intervention group (-4.6 (95% CI -5.7; -3.4) kg) and in the control group (-1.4 (95% CI, -2.6; -0.1) kg), but still more in the intervention group (P<.005)."

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. It is shown and described in Figure 1.

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

Ryd markering

1 2 3 4 5

subitem not at all important  ○  ○  ○  ●  ○  essential
Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. This is shown in Figure 1.

---

**14a) Dates defining the periods of recruitment and follow-up**

---

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. First of all "The study was carried out from April 2019 to October 2021". Participants were enrolled (baseline) from "April 16, 2018 to April 1, 2019". 6 months follow up and 12 month follow up was performed "This examination was equally completed after 6 and 12 months." and "The participants answered both questionnaires at baseline, 6- and 12-months follow up."

---

**14a–i) Indicate if critical “secular events” fell into the study period**

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

| 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|
| subitem not at all important | | | | | essential |
Does your paper address subitem 14a-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. COVID-19. "Due to the COVID-19 lockdown and national restrictions, some participants could not attend their 12-months assessment. Therefore, the 12-months assessment period was extended with four months, covering 12-16 months follow-up after baseline"

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This trial was not stopped or ended early.

15) A table showing baseline demographic and clinical characteristics for each group
NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. It is included in the article as table 1.
15-i) Report demographics associated with digital divide issues
In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

1 2 3 4 5
subitem not at all important  ○  ○  ○  ○  ● essential

Ryd markering

Does your paper address subitem 15-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. In table 1; "age, sex, education, occupational status, marital status" is included in categories

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple “denominators” and provide definitions
Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/ comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

1 2 3 4 5
subitem not at all important  ○  ○  ○  ○  ● essential

Ryd markering
Does your paper address subitem 16-i? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. In the tables and figures in the article the number analyzed is those who either completed 6 and/or 12 month. In supplementary the same analyses is performed on the participants completing 12 months. We also performed a per protocol analysis on those who used the app in at least 365 days = 12 months.

16-ii) Primary analysis should be intent-to-treat
Primary analysis should be intent-to-treat, secondary analyses could include comparing only “users”, with the appropriate caveats that this is no longer a randomized sample (see 18-i).

Does your paper address subitem 16-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Dit svar

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. It is available in table 2 in the paper.
17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as “average session length”. These must be accompanied by a technical description how a metric like a “session” is defined (e.g., timeout after idle time) [1] (report under item 6a).

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, but not that relevant in our outcomes.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
Does your paper address CONSORT subitem 18? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. In the text and in figure 2. "Within the intervention group the effect over time on BW reduction were equal in participants with and without T2D, but in the control group participants without T2D did not achieve a significant weight change (Figure 2)."

18-i) Subgroup analysis of comparing only users
A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

Does your paper address subitem 18-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

We performed a Per Protocol analysis. Doing the same analysis on only users for 12 months. Same results was found.

19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

No harms or unintended effect.
19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

1 2 3 4 5
subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Dit svar

DISCUSSION
22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

1 2 3 4 5

subitem not at all important ○ ○ ○ ● ○ essential

Does your paper address subitem 22-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. First the aim and primary outcome "The objective of this 12 months RCT, which was to see if individualized digital lifestyle coaching enabled by an eHealth tool could support obese participants with or without T2D to achieve and maintain a significant weight loss, was met after 12 months with a mean weight loss of 4.6 kg in the intervention group compared to 1.4 kg in the control group. " Later on the other outcomes " From baseline to 12 months, HbA1c was reduced in both the intervention and control group without a significant difference between the groups. This lack of difference was in contrast to a prior meta-analysis (25) and could not be explained by the small decrease in DPP4 use in the intervention group." and "Systolic blood pressure was significantly reduced in both groups at 12 months follow-up and without significant between-group difference, which might reflect that the blood pressure reduction was a consequence of participating in the study (healthy participator effect) and secondary to the weight loss"
22-ii) Highlight unanswered new questions, suggest future research
Highlight unanswered new questions, suggest future research.

| 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|-----------|
| ○ | ○ | ○ | ○ | ● |           |

Does your paper address subitem 22-ii?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. Further long-term research on the intervention and HbA1c: "However, the relatively high number of dropouts reduced power making subgroup analysis in participants with T2D difficult with high risk of false negative results which may explain the non-significant effect of the intervention on HbA1c." and we need a larger sample size and longer follow-up to conclude the long-term impact on HbA1c and further research to evaluate socioeconomic, educational, psychological, and physiological factors influence on user adherence.

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials
Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

| 1 | 2 | 3 | 4 | 5 | essential |
|---|---|---|---|---|-----------|
| ○ | ○ | ○ | ○ | ● |           |

Ryd markering
21) Generalisability (external validity, applicability) of the trial findings
NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalisability to other populations
Generalisability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

1 2 3 4 5
subitem not at all important ☐ ☐ ☐ ☐ ☐ essential

Ryd markering

Does your paper address subitem 21-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks “like this” to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes. "All the participants randomized to intervention and who stayed in the study used the eHealth tool indicating that if the eHealth tool is used in the future, the therapist will quickly be able to identify who is not satisfied by using the individualized digital coaching. For these subjects, it will be possible for the therapist to recommend other treatment strategies." and with the relatively low cost of the intervention a large scale up seems possible.
21-i) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ○ essential

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Dit svar

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Both in abstract: "ClinicalTrials.gov NCT03788915; https://clinicaltrials.gov/ct2/show/NCT03788915" and in the manuscript: "The study is registered in clinicaltrials.gov (NCT03788915)."

24) Where the full trial protocol can be accessed, if available
Does your paper address CONSORT subitem 24? *
Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. References to the study protocol included in the manuscript.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study.

Yes. Mentioned in acknowledgement: "This study acquired no external funding. All authors have been covered by their employment at the University of Southern Denmark. Except DHL has been covered by LIVA Healthcare A/S, that also paid for the coaching and utensils used in the study. A formal research agreement has been made between the University of Southern Denmark and LIVA Healthcare A/S to guarantee that LIVA Healthcare A/S could not influence any results of the study and in any doubt JS and the University of Southern Denmark would have the last saying."

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated
In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

1 2 3 4 5

subitem not at all important ○ ○ ○ ○ ● essential

Ryd markering
About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

- yes, major changes
- yes, minor changes
- no

What were the most important changes you made as a result of using this checklist?

Changes to the abstract. More information in the method section.

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

I spend a day going through this checklist.
As a result of using this checklist, do you think your manuscript has improved? *

- yes
- no
- Andet:

Would you like to become involved in the CONSORT EHEALTH group?
This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

- yes
- no
- Andet:

Any other comments or questions on CONSORT EHEALTH

Dit svar

STOP - Save this form as PDF before you click submit
To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit!
Click submit so we have your answers in our database!
Indsend aldrig adgangskoder via Google Analyse.

Dette indhold er hverken oprettet eller godkendt af Google. Rapportér misbrug - Servicevilkår - Privatlivspolitik

Google Analyse